You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Huge Alerts.

BSEM JUST PROVED PROFITABILITY IS NOT A FLUKE—SEVEN STRAIGHT WINNING QUARTERS, CLINICAL DOMINANCE, AND A POTENTIAL NASDAQ MOVE ARE PUTTING THIS MEDTECH NAME ON THE RADAR FOR 2026

BioStem Technologies (BSEM) is doing what most small-cap MedTech companies never achieve: delivering consistent profitability while scaling adoption in a massive, underpenetrated market.

Q3 2025 marked BSEM’s seventh consecutive quarter of positive adjusted EBITDA, alongside $10.5 million in revenue and $0.8 million in GAAP net income. Backed by $27.2 million in cash and industry-leading gross margins, the company has shown it can navigate reimbursement shifts without sacrificing financial discipline—an increasingly rare trait in regenerative medicine.

What truly separates BSEM is its clinically validated BioREtain® technology, supported by Level 1 randomized trial data showing dramatically better outcomes than standard of care in diabetic foot ulcers.

With expansion underway into the VA, Medicaid, hospitals, and ASCs—and a Nasdaq uplisting targeted for mid-2026—BioStem is positioning itself for greater institutional visibility and market re-rating. Add in a $25.50 Zacks price target, and this looks less like speculation and more like a company entering its next growth phase.

Start your due diligence now and decide whether BSEM belongs on your MedTech watchlist as 2026 catalysts unfold

We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.

We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of BioStem Technologies Inc. (OTC: BSEM) . The compensation consists of up to $6,500 and was received/will be received from Sideways Frequency.

This compensation should not be considered as an endorsement of the securities of BioStem Technologies Inc. (OTC: BSEM) and we are not responsible for any errors or omissions in any information provided about the securities of BioStem Technologies Inc. (OTC: BSEM) by Huge Alerts.

We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.

This disclosure is made as of 01/06/2026.

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.

Behind the Markets

You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here.